<p>药明康德（NASDAQ:ADPT - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 的股票研究分析师从 “持有” 评级上调至 “买入” 评级。</p>
<p>其他分析师最近也对该股票发布了研究报告。Piper Sandler 在周五的研究报告中对药明康德的股票设定了 21.00 美元的目标价。摩根大通将药明康德的目标价从 20.00 美元上调至 21.00 美元，并在周五的研究报告中给予该股票 “超配” 评级。Guggenheim 在 1 月 26 日的研究报告中将药明康德的目标价从 20.00 美元上调至 21.00 美元，并给予公司 “买入” 评级。BTIG Research 在周五的研究报告中将药明康德的目标价从 21.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。最后，TD Cowen 在周五的报告中重申了对药明康德股票的 “买入” 评级。八位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “适度买入”，共识目标价为 17.56 美元。</p>
<p><strong>获取我们对 ADPT 的最新分析</strong></p>
<h2>药明康德股票下跌 4.3%</h2>
<p>药明康德的股票在周五开盘价为 15.77 美元。该股票的 50 日移动平均线为 17.03 美元，200 日移动平均线为 15.23 美元。公司的市值为 24.1 亿美元，市盈率为-39.42，贝塔值为 2.18。药明康德的 52 周低点为 6.26 美元，52 周高点为 20.76 美元。</p>
<p>药明康德（NASDAQ:ADPT - 获取免费报告）最后一次发布财报是在 2 月 5 日，周四。公司报告本季度每股收益为（0.09 美元），超出共识预期的（0.19 美元）0.10 美元。该季度的营业收入为 7168 万美元，而共识预期为 5938 万美元。药明康德的股本回报率为-48.73%，净利润率为-21.48%。该季度的营业收入较去年同期增长了 51.0%。去年同期，公司每股收益为（0.23 美元）。整体来看，研究分析师预计药明康德在本年度将发布-0.92 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，首席执行官 Chad M. Robins 在 2 月 2 日周一出售了 124,998 股药明康德的股票。股票以平均价格 18.44 美元出售，总价值为 2,304,963.12 美元。交易后，首席执行官持有公司 2,459,245 股股票，价值为 45,348,477.80 美元。此次交易使其持股减少了 4.84%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席财务官 Kyle Piskel 在 2 月 4 日周三出售了 2,145 股该股票。股票以平均价格 18.46 美元出售，总交易额为 39,596.70 美元。出售后，首席财务官直接持有 216,637 股公司股票，价值为 3,999,119.02 美元。此次交易使其持股减少了 0.98%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士出售了价值 27,754,413 美元的 1,612,461 股公司股票。公司内部人士持有 6.40% 的股票。</p>
<h2>药明康德的机构交易</h2>
<p>一些机构投资者最近对该公司的持股进行了调整。Sound Income Strategies LLC 在第三季度获得了药明康德的新头寸，价值约为 30,000 美元。EverSource Wealth Advisors LLC 在第四季度将其在药明康德的持股增加了 197.1%。EverSource Wealth Advisors LLC 目前拥有 2,359 股公司股票，价值 38,000 美元，此前在上个季度增持了 1,565 股。Assetmark Inc.在第四季度将其在药明康德的持股增加了 867.9%。Assetmark Inc.目前拥有 3,020 股公司股票，价值 49,000 美元，此前在上个季度增持了 2,708 股。Smartleaf Asset Management LLC 在第三季度将其在药明康德的持股增加了 593.5%。Smartleaf Asset Management LLC 目前拥有 3,939 股公司股票，价值 59,000 美元，此前在上个季度增持了 3,371 股。最后，未来资产全球投资有限公司在第四季度将其在药明康德的持股增加了 26.0%。未来资产全球投资有限公司目前拥有 7,419 股公司股票，价值 120,000 美元，此前在上个季度增持了 1,532 股。机构投资者和对冲基金持有公司 99.17% 的股票。</p>
<h2>影响药明康德的关键故事</h2>
<p>以下是本周影响药明康德的关键新闻故事：</p>
<ul>
<li>积极情绪：第四季度业绩超出预期——ADPT 报告每股亏损 0.09 美元，低于市场共识的 0.19 美元亏损，营收为 7170 万美元（同比增长 51%），投资者通常将其视为对增长前景的积极信号。阅读更多。</li>
<li>积极情绪：分析师上调评级/目标价——摩根大通将其目标价上调至 21 美元，并维持超配评级，暗示与近期水平相比有显著上行空间，可能支持买入兴趣。阅读更多。</li>
<li>中性情绪：多位分析师的报告和覆盖：Zacks 及其他媒体发布了详细信息并与预估进行了比较；市场共识仍为 “适度买入”，平均目标价接近中十几到低 20 美元——提供了有用的背景，但不是单一催化剂。阅读更多。</li>
<li>中性情绪：完整的财报材料和会议记录可供深入审阅（管理层评论和幻灯片将指导收入质量和指引是否合理化此次反弹）。阅读更多。</li>
<li>消极情绪：本周披露了显著的内部人士卖出——首席执行官 Chad M. Robins 及其他内部人士出售了大量股份（首席执行官约 12.5 万股；其他内部人士的卖出也有报告）。即使业绩强劲，大规模的内部人士卖出也可能对情绪造成压力。阅读更多。</li>
<li>消极情绪：公司仍处于亏损状态，负毛利率和负股本回报率；分析师仍预计全年亏损（共识每股收益为负），这使得估值和盈利时机成为持续的投资者担忧。阅读更多。</li>
<li>中性情绪：本批次报告的空头头寸数据实际上为零/未变，显示没有立即的空头挤压动态；计算的覆盖天数为 0.0，因此空头头寸不是当前市场驱动因素。（该项在最近的数据中被标记。）</li>
</ul>
<h2>Adaptive Biotechnologies 公司简介</h2>
<p>(获取免费报告)</p>
<p>Adaptive Biotechnologies 是一家临床阶段的生物技术公司，专注于利用适应性免疫系统来转变疾病的诊断和治疗。通过专有的免疫受体测序和分析，该公司解码 T 细胞和 B 细胞受体的遗传信息，以识别免疫反应的特征。其核心技术平台提供对免疫驱动条件的洞察，使得更精确的监测和针对性治疗开发成为可能。</p>
<p>该公司的旗舰产品 immunoSEQ 为研究人员和制药合作伙伴提供高通量免疫库分析。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Adaptive Biotechnologies</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Adaptive Biotechnologies 吗？</h2>
<p>在考虑投资 Adaptive Biotechnologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Adaptive Biotechnologies 并不在名单上。</p>
<p>虽然 Adaptive Biotechnologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

ADPT

<p>华尔街禅将 Adaptive Biotechnologies（纳斯达克代码：ADPT）的评级从 “持有” 上调至 “买入”。其他分析师，包括 Piper Sandler 和摩根大通，也将其目标价格上调至 21.00 美元。该股票目前被评为 “适度买入”，共识目标价格为 17.56 美元。尽管最近下跌了 4.3%，但公司报告的收入同比增长了 51%。内部交易活动中，首席执行官 Chad M. Robins 和首席财务官 Kyle Piskel 进行了大量股票出售。机构投资者最近也增加了对公司的持股</p>

<p>Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Sunday.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:ADPT - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 的股票研究分析师从 “持有” 评级上调至 “买入” 评级。</p>
</div><p>Other analysts also recently issued research reports about the stock. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday. JPMorgan Chase &amp; Co. increased their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday. Guggenheim raised their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, January 26th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday. Finally, TD Cowen reiterated a &#34;buy&#34; rating on shares of Adaptive Biotechnologies in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.56.</p>
<div class="lb-trans"><p>其他分析师最近也对该股票发布了研究报告。Piper Sandler 在周五的研究报告中对药明康德的股票设定了 21.00 美元的目标价。摩根大通将药明康德的目标价从 20.00 美元上调至 21.00 美元，并在周五的研究报告中给予该股票 “超配” 评级。Guggenheim 在 1 月 26 日的研究报告中将药明康德的目标价从 20.00 美元上调至 21.00 美元，并给予公司 “买入” 评级。BTIG Research 在周五的研究报告中将药明康德的目标价从 21.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。最后，TD Cowen 在周五的报告中重申了对药明康德股票的 “买入” 评级。八位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “适度买入”，共识目标价为 17.56 美元。</p>
</div><p><strong>Get Our Latest Analysis on ADPT</strong></p>
<div class="lb-trans"><p><strong>获取我们对 ADPT 的最新分析</strong></p>
</div><h2>Adaptive Biotechnologies Stock Down 4.3%</h2>
<div class="lb-trans"><h2>药明康德股票下跌 4.3%</h2>
</div><p>Shares of Adaptive Biotechnologies stock opened at $15.77 on Friday. The stock's fifty day moving average is $17.03 and its two-hundred day moving average is $15.23. The company has a market capitalization of $2.41 billion, a PE ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies has a 52 week low of $6.26 and a 52 week high of $20.76.</p>
<div class="lb-trans"><p>药明康德的股票在周五开盘价为 15.77 美元。该股票的 50 日移动平均线为 17.03 美元，200 日移动平均线为 15.23 美元。公司的市值为 24.1 亿美元，市盈率为-39.42，贝塔值为 2.18。药明康德的 52 周低点为 6.26 美元，52 周高点为 20.76 美元。</p>
</div><p>Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The business's revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period last year, the company earned ($0.23) earnings per share. As a group, research analysts anticipate that Adaptive Biotechnologies will post -0.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:ADPT - 获取免费报告）最后一次发布财报是在 2 月 5 日，周四。公司报告本季度每股收益为（0.09 美元），超出共识预期的（0.19 美元）0.10 美元。该季度的营业收入为 7168 万美元，而共识预期为 5938 万美元。药明康德的股本回报率为-48.73%，净利润率为-21.48%。该季度的营业收入较去年同期增长了 51.0%。去年同期，公司每股收益为（0.23 美元）。整体来看，研究分析师预计药明康德在本年度将发布-0.92 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, CEO Chad M. Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the transaction, the chief executive officer owned 2,459,245 shares of the company's stock, valued at $45,348,477.80. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CFO Kyle Piskel sold 2,145 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total transaction of $39,596.70. Following the sale, the chief financial officer directly owned 216,637 shares of the company's stock, valued at $3,999,119.02. The trade was a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,612,461 shares of company stock worth $27,754,413 in the last three months. 6.40% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Chad M. Robins 在 2 月 2 日周一出售了 124,998 股药明康德的股票。股票以平均价格 18.44 美元出售，总价值为 2,304,963.12 美元。交易后，首席执行官持有公司 2,459,245 股股票，价值为 45,348,477.80 美元。此次交易使其持股减少了 4.84%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席财务官 Kyle Piskel 在 2 月 4 日周三出售了 2,145 股该股票。股票以平均价格 18.46 美元出售，总交易额为 39,596.70 美元。出售后，首席财务官直接持有 216,637 股公司股票，价值为 3,999,119.02 美元。此次交易使其持股减少了 0.98%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士出售了价值 27,754,413 美元的 1,612,461 股公司股票。公司内部人士持有 6.40% 的股票。</p>
</div><h2>Institutional Trading of Adaptive Biotechnologies</h2>
<div class="lb-trans"><h2>药明康德的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the business. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. grew its stake in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after acquiring an additional 2,708 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company's stock valued at $59,000 after acquiring an additional 3,371 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Adaptive Biotechnologies by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company's stock valued at $120,000 after purchasing an additional 1,532 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近对该公司的持股进行了调整。Sound Income Strategies LLC 在第三季度获得了药明康德的新头寸，价值约为 30,000 美元。EverSource Wealth Advisors LLC 在第四季度将其在药明康德的持股增加了 197.1%。EverSource Wealth Advisors LLC 目前拥有 2,359 股公司股票，价值 38,000 美元，此前在上个季度增持了 1,565 股。Assetmark Inc.在第四季度将其在药明康德的持股增加了 867.9%。Assetmark Inc.目前拥有 3,020 股公司股票，价值 49,000 美元，此前在上个季度增持了 2,708 股。Smartleaf Asset Management LLC 在第三季度将其在药明康德的持股增加了 593.5%。Smartleaf Asset Management LLC 目前拥有 3,939 股公司股票，价值 59,000 美元，此前在上个季度增持了 3,371 股。最后，未来资产全球投资有限公司在第四季度将其在药明康德的持股增加了 26.0%。未来资产全球投资有限公司目前拥有 7,419 股公司股票，价值 120,000 美元，此前在上个季度增持了 1,532 股。机构投资者和对冲基金持有公司 99.17% 的股票。</p>
</div><h2>Key Stories Impacting Adaptive Biotechnologies</h2>
<div class="lb-trans"><h2>影响药明康德的关键故事</h2>
</div><p>Here are the key news stories impacting Adaptive Biotechnologies this week:</p>
<div class="lb-trans"><p>以下是本周影响药明康德的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.</li>
<li>Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.</li>
<li>Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a &#34;Moderate Buy&#34; with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.</li>
<li>Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.</li>
<li>Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.</li>
<li>Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.</li>
<li>Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第四季度业绩超出预期——ADPT 报告每股亏损 0.09 美元，低于市场共识的 0.19 美元亏损，营收为 7170 万美元（同比增长 51%），投资者通常将其视为对增长前景的积极信号。阅读更多。</li>
<li>积极情绪：分析师上调评级/目标价——摩根大通将其目标价上调至 21 美元，并维持超配评级，暗示与近期水平相比有显著上行空间，可能支持买入兴趣。阅读更多。</li>
<li>中性情绪：多位分析师的报告和覆盖：Zacks 及其他媒体发布了详细信息并与预估进行了比较；市场共识仍为 “适度买入”，平均目标价接近中十几到低 20 美元——提供了有用的背景，但不是单一催化剂。阅读更多。</li>
<li>中性情绪：完整的财报材料和会议记录可供深入审阅（管理层评论和幻灯片将指导收入质量和指引是否合理化此次反弹）。阅读更多。</li>
<li>消极情绪：本周披露了显著的内部人士卖出——首席执行官 Chad M. Robins 及其他内部人士出售了大量股份（首席执行官约 12.5 万股；其他内部人士的卖出也有报告）。即使业绩强劲，大规模的内部人士卖出也可能对情绪造成压力。阅读更多。</li>
<li>消极情绪：公司仍处于亏损状态，负毛利率和负股本回报率；分析师仍预计全年亏损（共识每股收益为负），这使得估值和盈利时机成为持续的投资者担忧。阅读更多。</li>
<li>中性情绪：本批次报告的空头头寸数据实际上为零/未变，显示没有立即的空头挤压动态；计算的覆盖天数为 0.0，因此空头头寸不是当前市场驱动因素。（该项在最近的数据中被标记。）</li>
</ul>
</div><h2>Adaptive Biotechnologies Company Profile</h2>
<div class="lb-trans"><h2>Adaptive Biotechnologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.</p>
<div class="lb-trans"><p>Adaptive Biotechnologies 是一家临床阶段的生物技术公司，专注于利用适应性免疫系统来转变疾病的诊断和治疗。通过专有的免疫受体测序和分析，该公司解码 T 细胞和 B 细胞受体的遗传信息，以识别免疫反应的特征。其核心技术平台提供对免疫驱动条件的洞察，使得更精确的监测和针对性治疗开发成为可能。</p>
</div><p>The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.</p>
<div class="lb-trans"><p>该公司的旗舰产品 immunoSEQ 为研究人员和制药合作伙伴提供高通量免疫库分析。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Adaptive Biotechnologies</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Adaptive Biotechnologies</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ADPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adaptive Biotechnologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Adaptive Biotechnologies 吗？</h2>
</div><p>Before you consider Adaptive Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Adaptive Biotechnologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Adaptive Biotechnologies 并不在名单上。</p>
</div><p>While Adaptive Biotechnologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adaptive Biotechnologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Adaptive Biotechnologies（纳斯达克代码：ADPT）的股票评级被华尔街 Zen 上调